Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don't go through ...

Christopher Biggins has revealed he's using the medication Mounjaro and has credited it for his dramatic transformation as he ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Novo Nordisk's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Actor Christopher Biggins has revealed he is using weight loss jabs as he needed to lose weight after having surgery on his knee. Porridge star Biggins, 76, said he is taking Mounjaro, which is made ...

The company said Friday that it received FDA approval for a new Wegovy indication as a treatment of a fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH, in adults ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...